Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation

High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension
Arrigo F G CiceroClaudio Borghi

Abstract

Fenofibrate is an effective and safe treatment for hypertriglyceridemia. However, after TG reduction a residual dyslipidemia could appear and require further treatment. To comparatively evaluate the short-term tolerability and efficacy of a combined lipid-lowering nutraceutical and pravastatin 40 mg in fenofibrate treated patients. We prospectively enrolled 40 patients well-tolerating treatment with micronized fenofibrate 145 mg/day and with residual dyslipidemia (LDL-C > 115 mg/dL and TG > 150 mg/dL). Exclusion criteria have been type 2 diabetes, Familial Hypercholesterolemia, previous cardiovascular diseases and severe chronic kidney disease. Then, we have randomly assigned the patients to treatment with pravastatin 40 mg or a combined lipid-lowering nutraceutical (Armolipid Plus®, containing monacolin 3 mg and berberine 500 mg). After 8 weeks of treatment, 80% of pravastatin treated patients (N. 16/20) and 75% of those treated with Armolipid Plus® (N. 15/20) reached the desired LDL-C target, while 50% of pravastatin treated patients (N. 10/20) and 80% of the Armolipid Plus® treated ones reached the desired TG target (N. 16/20). No one adverse event has been registered during Armolipid Plus®, while 1 patient claimed myalgia a...Continue Reading

References

Sep 24, 2008·Expert Opinion on Investigational Drugs·Theodosios Filippatos, Haralampos J Milionis
Jan 18, 2013·Clinical and Experimental Pharmacology & Physiology·Qiang GengWenqing Liang
Jul 22, 2014·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Antonio Hernández Mijares
Sep 20, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Giuseppe DerosaAmirhossein Sahebkar
May 10, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Matteo PirroAmirhossein Sahebkar
May 18, 2016·The American Journal of Cardiology·Matthew Budoff
Jun 21, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Amirhossein SahebkarLuisa Costanzo
Sep 1, 2016·Journal of Clinical Lipidology·Kevin C MakiMichael H Davidson
Mar 1, 2017·Vascular Health and Risk Management·Nicola TarantinoNatale Daniele Brunetti
May 26, 2017·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Arrigo Francesco Giuseppe CiceroClaudio Borghi
Sep 9, 2017·Archives of Medical Science : AMS·Arrigo F G CiceroMaciej Banach
Jun 30, 2018·Journal of the American College of Cardiology·Maciej BanachUNKNOWN International Lipid Expert Panel (ILEP)

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

International Journal of Clinical Pharmacology and Therapeutics
R FogariP Preti
Cardiovascular Drugs and Therapy
Sergio Fazio
Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis
Jesús Millán Núñez-Cortés
© 2022 Meta ULC. All rights reserved